The importance of Notch signaling in peripheral T-cell lymphomas

References

• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281–1284.
   PubMed Web of Science ®Google Scholar
• Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol 2007;127:707–722.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496–5504.
   PubMed Web of Science ®Google Scholar
• Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284:770–776.
   PubMed Web of Science ®Google Scholar
• Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649–661.
   PubMed Web of Science ®Google Scholar
• Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009;113:856–865.
   PubMed Web of Science ®Google Scholar
• Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk.Lymphoma 2001;42:467–472.
   PubMed Web of Science ®Google Scholar
• Weng AP, Ferrando AA, Lee W et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269–271.
   PubMed Web of Science ®Google Scholar
• Kamstrup MR, Ralfkiaer E, Skovgaard GL, et al. Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 2008;158:747–753.
   PubMed Web of Science ®Google Scholar
• Kamstrup MR, Gjerdrum LM, Biskup E, et al. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood 2010;116:2504–2512.
   PubMed Web of Science ®Google Scholar
• Kamstrup MR, Biskup E, Gniadecki R. Notch signalling in primary cutaneous CD30 + lymphoproliferative disorders: a new therapeutic approach?. Br J Dermatol 2010;163:781–788.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988;72:234–240.
   PubMed Web of Science ®Google Scholar
• Rizzo P, Osipo C, Foreman K, et al. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124–5131.
   PubMed Web of Science ®Google Scholar
• Ando T, Kawabe T, Ohara H, et al. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem 2001;276:42971–42977.
   PubMed Web of Science ®Google Scholar
• Hubinger G, Muller E, Scheffrahn I, et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 2001;20:590–598.
   PubMed Web of Science ®Google Scholar
• Hu C, Dievart A, Lupien M, et al. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol 2006;168:973–990.
   PubMedGoogle Scholar
• Pinnix CC, Lee JT, Liu ZJ, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 2009;69: 5312–5320.
   PubMed Web of Science ®Google Scholar
• Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530–8537.
   PubMed Web of Science ®Google Scholar
• van der FL, Qin Y, Out-Luiting JJ, et al. NOTCH1 signaling as a therapeutic target in Sezary syndrome. J Invest Dermatol 2012;132: 2810–2817.
   PubMed Web of Science ®Google Scholar
• Balint K, Xiao M, Pinnix CC, et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 2005;115:3166–3176.
   PubMed Web of Science ®Google Scholar
• Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530–8537.
   PubMed Web of Science ®Google Scholar
• Jundt F, Anagnostopoulos I, Forster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002;99:3398–3403.
   PubMed Web of Science ®Google Scholar
• Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996;183:2283–2291.
   PubMed Web of Science ®Google Scholar
• Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389–1401.
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101–105.
   PubMed Web of Science ®Google Scholar
• Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007;204:1825–1835.
   PubMed Web of Science ®Google Scholar
• Lee SY, Kumano K, Nakazaki K, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009;100:920–926.
   PubMed Web of Science ®Google Scholar
• Troen G, Wlodarska I, Warsame A, et al. NOTCH2 mutations in marginal zone lymphoma. Haematologica 2008;93:1107–1109.
   PubMed Web of Science ®Google Scholar
• Krop I, Demuth T, Guthrie T, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012;30:2307–2313.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006;24(Suppl. 15): Abstract 6585.
   Google Scholar
• Curry CL, Reed LL, Golde TE, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005;24:6333–6344.
   PubMed Web of Science ®Google Scholar
• Rasul S, Balasubramanian R, Filipovic A, et al. Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer 2009;100:1879–1888.
   PubMed Web of Science ®Google Scholar
• Rizzo P, Miao H, D’Souza G, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008;68:5226–5235.
   PubMed Web of Science ®Google Scholar
• Han J, Ma I, Hendzel MJ, et al. The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. Breast Cancer Res 2009;11:R57.
   Web of Science ®Google Scholar
• Meng X, Matlawska-Wasowska K, Girodon F, et al. GSI-I (Z-LLNle-CHO) inhibits gamma-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia. Leukemia 2011; 25:1135–1146.
   PubMed Web of Science ®Google Scholar
• Biskup E, Kamstrup M, Manfé V, et al. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma. Br J Dermatol 2013;168:504–512.
   PubMed Web of Science ®Google Scholar